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Abstract 
Background: Assembled virus-like particles (VLPs) without genetic material, with structure similar to infectious 
virions, have been successfully used as vaccines. We earlier described in vitro assembly, characterisation and tissue 
specific receptor dependent Clathrin mediated entry of empty HEV VLPs, produced from Escherichia coli expressed 
HEV capsid protein (pORF2). Similar VLP’s have been described as a potential candidate vaccine (Hecolin) against HEV.
Findings: We have attempted to use such recombinant assembled Hepatitis E virus (HEV) VLPs as a carrier for het-
erologous RNA with protein coding sequence fused in-frame with HEV 5′ region (containing cap and encapsidation 
signal) and investigated, if the relevant protein could be expressed and elicit an immune response in vivo. In vitro 
transcribed red fluorescent protein (RFP)/Hepatitis B virus surface antigen (HBsAg) RNA, fused to 5′-HEV sequence 
with cap and encapsidation signal (1–249 nt), was packaged into the recombinant HEV-VLPs and incubated with five 
different cell lines (Huh7, A549, Vero, HeLa and SiHa). The pORF2-VLPs could specifically transfer exogenous coding 
RNA into Huh7 and A549 cells. In vivo, Balb/c mice were immunized (intramuscular injections) with 100 µg pORF2-VLP 
encapsidated with 5′-methyl-G-HEV (1–249 nt)-HBsAg RNA, blood samples were collected and screened by ELISA for 
anti-pORF2 and anti-HBsAg antibodies. Humoral immune response could be elicited in Balb/c mice against both HEV 
capsid protein and cargo RNA encoded HBsAg protein.
Conclusions: These findings suggest that other than being a possible vaccine, HEV pORF2-VLPs can be used as a 
promising non-replicative tissue specific gene delivery system.
Keywords: Hepatitis E virus, Virus like particles, RNA-VLP complex, Chimeric RNA, HBsAg
© 2015 Panda et al. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License 
(http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, 
provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, 
and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/
publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Findings
VLPs inherit most of the properties of parent virus, like 
capability of self-assembly into organised structure, spe-
cific interaction with nucleic acid/protein, and cell-spe-
cific entry. These replication-deficient, non-infectious, 
nano-structured particles can be useful if they can effec-
tively deliver therapeutically useful nucleic acid, drug, 
targeting peptide or a conjugated imaging molecule.
We had described generation of HEV VLP’s from 
Escherichia coli produced capsid protein [1]. Trans-
mission electron microscopy (TEM) and nanoparticle 
tracking analysis (a rapid and direct NTA technique for 
real-time visualization of nanoparticles in liquid) showed 
HEV VLP’s as uniform particles of ~30–35  nm in size, 
consistent with the size of infectious HEV virions. The 
specificity of HEV-VLP binding and entry into the liver 
cells was demonstrated using reporter linked fluorescent 
VLP’s [1]. Similar bacterially generated VLPs (HEV 239) 
have been licensed as a potential candidate vaccine (Hec-
olin) against HEV in China [2–4].
Here, we investigate whether (1) empty VLPs of HEV 
could encapsidate heterologous RNA fused with encap-
sidation signal and deliver the exogenous RNA in a cell 
specific manner as a nanocarrier? (2) Can the foreign 
gene be translated from delivered chimeric RNA? and (3) 
If injected to animals, can the RNA-VLP complex induce 
immunity to both the carrier HEV capsid protein and 
the protein expressed from delivered RNA? To study the 
above possibilities, we generated a chimeric RNA where 
reporter/antigen producing gene/coding sequence (RFP/
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HBsAg) is fused in-frame with the HEV 5′ RNA region 
containing cap and encapsidation signal.
Encapsidation of HEV‑VLPs with in vitro transcribed RNA
Based on RNA secondary structure prediction software 
(mfold), it was found that HEV 5′-end [which contains 5′ 
non-coding region (NCR) of HEV (1–28 nt) and initial 
coding region of ORF1 (29–249 nt)] bears three stem-
loop structures viz. SLI (165–177 nt), SLII (179–210 
nt), and SLIII (213–231 nt) (Figure  1). These stem-loop 
structures are possibly responsible for interaction with 
HEV capsid protein. SLI and SLII are particularly impor-
tant as similar structures (165–206 nt) are known to be 
conserved among most of the alphaviruses such as Sind-
bis, semliki Forest and Highlands J virus [5]. SLIII on the 
other hand, is not absolutely essential but may function 
to enhance the interaction of RNA with HEV capsid pro-
tein. We observed that the arrangement of HEV stem-
loop structures SLI (165–177 nt) and SLII (179–210 nt), 
remained conserved even after in-frame fusion with for-
eign RNA (RFP/HBsAg), indicating their formation and 
stability in chimeric RNA (Figure 1).
The capped RNA transcripts with poly(A) tail 
[5′-methyl-G-RFP, 5′-methyl-G-HBsAg, 5′-methyl-G-
HEV(1–249 nt)-RFP, 5′-methyl-G-HEV(199–444 nt)-RFP, 
5′-methyl-G-HEV(1–249  nt)-HBsAg and 5′-methyl-G-
HEV(199–444 nt)-HBsAg] (Figure 2A) were produced by 
T7 RNA polymerase (from their respective pGEMT easy-
DNA constructs, Figure 2A) using mMessage mMachine 
T7 Ultra Transcription kit (Ambion) according to the 
manufacturer’s instruction and the integrity of synthe-
sized RNA was checked on 5% urea-acrylamide gel (Fig-
ure 2B, C). The HEV, pORF2 and N-terminal (Δ1-112aa) 
deleted pORF2 VLPs were synthesized as described 
earlier [1], and encapsidated separately with different 
heterologous RNA molecules using direct interaction 
method [6]. After the packaging of RNA, HEV-VLP com-
plexes were treated with RNase A to degrade the unpack-
aged RNA.
Internalization of HEV‑RNA‑VLP complex into the cultured 
cells
To ascertain the feasibility of synthetic VLPs as a vehi-
cle for nucleic acid delivery, we checked the expression 
of protein encoded from packaged foreign RNA (RFP/
HBsAg) in five different cell lines i.e.; Huh7, A549, Vero, 
HeLa and SiHa. Freshly harvested cells (5  ×  104 cells) 
were plated, allowed to adhere and incubated separately 
with 250 nM (saturation binding concentration based on 
our earlier work [1]) of various RNA-VLP complexes. At 
various time points, post incubation (12, 24, 36, 48, 72 h; 
data shown for only 48 h), the cells were observed under 
confocal microscope using Hybrid detector (HyD) at 
561 nm to check the fluorescence from RFP protein. Sim-
ilar experiments were conducted for pORF2-VLPs encap-
sidated with 5′-methyl-G-HEV(1–249  nt)-HBsAg RNA 
and Indirect immunofluorescence assay was performed 
and [7] observed under inverted fluorescent microscope 
(Nikon TE2000-U) for the expression of HBsAg protein. 
The entry and internalization of pORF2 f-VLP’s (pro-
duced from ORF2-linker EGFP protein) has been previ-
ously demonstrated by us in Huh-7 cells [1]. However, 
in the present experiments, due to the lower concentra-
tion (250 nM) of RNA-VLP complex, immunofluorescent 
staining with anti-pORF2 could not be observed in RNA-
VLP complex infected cells.
It was observed that RNA-VLP complex [prepared 
from 5′-methyl-G-HEV(1–249  nt)-RFP RNA and 
pORF2 VLP’s] specifically entered liver cells (Huh7; 









Figure 1 RNA secondary structure prediction using mfold program. Secondary structure prediction of a HEV (1–249 nt) RNA, b HEV (1–249 nt)-
HBsAg RNA and c HEV (1–249 nt)-RFP RNA, using mfold program, based on free energy calculations.
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fluorescence of expressed RFP (48  h post incubation) 
as well as expression of HBsAg protein, visualized by 
indirect immunofluorescence with anti-HBsAg anti-
body (48  h post incubation, Figure  3ci–iii). However, 
no signal was observed when Vero, SiHa and HeLa cells 
were used, indicating a cell specific entry of HEV VLP’s 
(Figure 3ai–v).
Parallel control experiments were performed, where 
Huh7 cells were incubated with only 5′-methyl-G-
HEV (1–249  nt)-RFP RNA (Figure  3bi), and RNA-
VLP complexes prepared from 5′-methyl-G-HEV 
(199–444  nt)-RFP RNA and pORF2-VLPs (Figure  3bii), 
5′-methyl-G-HEV (199–444  nt)-HBsAg RNA and 
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Figure 2 A Schematic representation of in vitro transcribed RNA constructs. a 5′-methyl-G-RFP, b 5′-methyl-G-HBsAg, c 5′-methyl-G-HEV-(1–249 nt)-
RFP, d 5′-methyl-G-HEV-(1–249 nt)-HBsAg, e 5′-methyl-G-HEV-(199–444 nt)-RFP, f 5′-methyl-G-HEV-(199–444 nt)-HBsAg. B Urea gel representing 
integrity of various in vitro transcribed RNAs (with 5′ cap and 3′ poly-A tail). Lane 1 5′-methyl-G-HEV-(1–249 nt)-RFP (947 bp); lane 2 5′-methyl-G-RFP 
(698 bp); lane 3 5′-methyl-G-HBsAg, (677 bp); lane 4 5′-methyl-G-HEV-(1–249 nt)-HBsAg (926 bp); lane M RNA Millenium marker (Ambion). The size 
of all above transcribed RNAs in gel, seems greater by 30–50 nt, due to 3′ poly-A tail added to them. C Urea gel representing integrity of various in 
vitro transcribed RNAs (with 5′ cap and 3′ poly-A tail). Lane 1 5′-methyl-G-HEV-(199–444 nt)-RFP (943 bp); lane 2 5′-methyl-G-HEV-(199–444 nt)-HBsAg, 
(922 bp); lane M RNA Millenium marker (Ambion). The size of all above transcribed RNAs in gel, seems greater by 30–50 nt, due to 3′ poly-A tail 
added to them.
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RNA and N-terminal truncated Δ1-112aa pORF2-VLPs 
(Figure 3biii). However, in either case, no signal for RFP/
HBsAg could be observed till 72 h which (1) ruled out the 
possibility of any non-specific RNA entry and (2) showed 
the significance of N-terminal HEV encapsidation (1–249 
ntd) signal in mediating VLP entry (Figure 3).
Another control experiment was performed where 
5′-methyl-G-HEV (1–249  nt)-RFP RNA was annealed 
with complementary oligo (HEV, 150–200 ntd) and then 
packaged with pORF2-VLPs, which again showed no RFP 
signal in Huh7 cells (Figure  3biv) indicating the critical 
requirement of secondary structure and single stranded 
RNA for binding to HEV VLPs.
Balb/c mice immunization with HBsAg RNA‑pORF2 VLP 
complex and generation of Humoral immune response
After VLP-mediated internalization of foreign RNA 
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Figure 3 Internalisation of HEV-VLPs in different cell lines. a Confocal microscopy images for checking the expression of RFP in RNA-VLP [5′-methyl-
G-HEV(1–249 nt)-RFP RNA and pORF2 VLP’s] incubated i Huh7, ii A549, iii HeLa, iv Vero and v SiHa cells. b Confocal microscopy images for RFP 
fluorescence in Huh7 cells incubated with i 5′-methyl-G-HEV (1–249 nt)-RFP RNA only; RNA-VLP complexes prepared from ii 5′-methyl-G-HEV (199–
444 nt)-RFP RNA and pORF2-VLPs, iii 5′-methyl-G-HEV (1–249 nt)-RFP RNA and Δ112aa pORF2-VLPs, iv 5′-methyl-G-HEV(1–249 nt)-RFP RNA, annealed 
with complementary oligo (HEV, 150–200 nt) and pORF2-VLPs. c Fluorescent microscopy images (i–iii) of Immunofluorescence assay for HBV surface 
antigen (HBsAg) in Huh 7 cells, incubated with HEV(1–249 nt)-HBsAg-RNA-pORF2 VLPs. Indirect immunofluorescence assay was performed for 
detecting HBsAg expression using anti-HBsAg primary antibody followed by Alexa-546 conjugate secondary antibody.
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further studied the expression and immune response 
elicited in mice following the administration of RNA-
VLP complex. Four 6-week-old Balb/c mice were immu-
nized with intramuscular injections (in tibialis anterior) 
of 100  µg pORF2-VLP encapsidated with 5′-metly-G-
HEV (1–249  nt)-HBsAg RNA on days 0, 14, 25, 32, 39 
and 45 and blood samples were collected on days 10, 21, 
28, 35, 41, 48 and 52. Sera were screened by ELISA, as 
previously described [8], for the presence of antibod-
ies, both towards HBV surface antigen protein and HEV 
pORF2. Blood samples from four unimmunized mice 
served as negative controls in ELISA. Antibody against 
HBsAg as well as HEV capsid protein were detected in 
the immunized mice. The experimental mice showed 
maximal titer of anti-HBsAg and anti-pORF2 antibody 
on 41 and 48 days, respectively. (Figure 4a, b). Significant 
increase (**p < 0.01, t test) in antibody titre was observed 
for both anti-pORF2 and anti-HBsAg antibodies in 
immunised mice, as compared to un-immunized control 
mice.
Humoral immune response could be raised against 
both HEV pORF2 (monomeric unit of VLPs) and HBsAg 
protein (expressed from delivered hetrologous RNA), 
indicating the acceptance and processing of VLP-RNA 
complex as an effective antigen by host immune system. 
To our knowledge, this is the first direct demonstration 
of use of synthetic HEV VLPs for delivering RNA coding 
for a protein that acts as a potential immunogen in vivo.
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